The prostate cancer metabolome is characterized by an increased amino acid metabolism and a perturbation of nitrogen breakdown pathways (1), along with high total choline-containing compounds and phosphocholine levels (2) . With metabolomic profiling, tissue levels of sarcosine-an N-methyl derivative of the amino acid glycine and a metabolic product of choline ( Fig. 1 )-have been found to be elevated in localized prostate cancer compared with benign prostatic tissues. Tissue sarcosine levels have also been shown to increase during prostate cancer progression to metastatic disease (3) , and knockdown of glycine-N-methyltransferase-the enzyme that generates sarcosine from glycine-attenuates prostate cancer invasion. The addition of exogenous sarcosine, or knockdown of the mitochondrial enzyme that leads to sarcosine degradation (sarcosine dehydrogenase [SARDH] ), induces an invasive phenotype in benign prostate epithelial cells (4) . Furthermore, there is evidence for a strong sarcosine-related induction of genes involved particularly in cell cycle progression (5) . Sarcosine is therefore thought to be a potential oncometabolite rather than a nonproteinogenic amino acid (6) .
These data suggest a potential role of radiolabeled sarcosine for PET imaging. 11 C-choline and 18 F-fluorocholine are widely used PET radiopharmaceuticals for imaging of prostate cancer, particularly in the setting of prostate cancer recurrence (7) . At primary staging, 11 C-choline preferentially identifies intermediateand high-risk (i.e., clinically significant) prostate cancer, whereas low-risk lesions are typically not visualized (8, 9) . However, choline radiotracers are limited because of commonly observed increased retention in nodular benign prostatic hyperplasia (10) as well as unsatisfactory accuracy for nodal metastatic disease in initial staging (11) .
The purpose of this study was to assess the uptake mechanism of 11 C-sarcosine, to test its utility in common prostate cancer xenograft models in comparison to 11 C-choline using small-animal PET, and to provide first human evidence of its potential in localized prostate cancer.
MATERIALS AND METHODS

Radiotracer Synthesis
11 C-choline was synthesized by 11 C-methylation of N,N-dimethylaminoethanol with 11 C-methyl iodide (12) , whereas 11 C-acetate was prepared by bubbling 11 C-CO 2 through a solution of methyl-magnesium chloride (13) .
We radiolabeled 11 C-sarcosine by our standard 11 C-methylation method using 11 C-methyl triflate (14) , followed by saponification using aqueous sodium hydroxide at 60°C (Fig. 2) . After labeling, the reaction mixture was diluted with water and purified using an anionexchange solid-phase extraction cartridge. The final injectable dose was eluted with aqueous sodium chloride and filtered through a 0.22-mm sterile filter. Total synthesis time was approximately 25 min. Non-decay-corrected radiochemical yield was 2.5%-6% (non-decay-corrected yield based on 111 GBq of 11 C-CO 2 , n 5 5), and radiochemical purity was greater than 95%. Radiochemical identity was confirmed and quantified by standard high-performance liquid chromatography (i.e., calculating relative retention times). The mass of 11 C-sarcosine for human use was 10 nmol or less.
Cell Culture and Animal Experiments
All animal experiments were conducted in accordance with the Institutional Commission on the Ethical Treatment of Animals. Androgen receptor-positive (LNCaP) and -negative (DU-145 and PC-3) prostate cancer cell lines were obtained from American Type Culture Collection, and chemicals were purchased from Sigma-Aldrich. Genetically fingerprinted androgen receptor-positive (LNCaP) and -negative (DU-145, PC-3) prostate cancer cell lines were cultured in RPMI-1640 medium in the presence of 10% heat-inactivated fetal bovine serum, 1% penicillin/streptomycin, 2 mMol L-glutamine, and 1 mMol sodium pyruvate. Approximately 5 million LNCaP, DU-145, or PC-3 cells were injected into the flanks of 6-to 8-wk-old athymic nu/nu mice (Charles River). Animals were housed under pathogen-free conditions in microisolator cages, with rodent chow and water available ad libitum. Animals were examined daily, and body weight and tumor size were determined. The tumors were allowed to grow to a diameter of 4-6 mm (short axis) before imaging.
C-Sarcosine Cell Assays
The 11 C-sarcosine uptake of approximately 3 · 10 5 PC-3 and LNCaP tumor cells was determined (in triplicates) with and without the presence of increasing concentrations of unlabeled sarcosine. To determine the precision of uptake measurements, PC-3 cells were incubated in RPMI-1640 medium for 20 min with 9 kBq of 11 C-sarcosine, washed 3 times with ice-cold phosphate-buffered saline, and counted. The 11 C-sarcosine uptake was determined to be 12.5% 6 1.1% of the administered dose (n 5 12). 11 C-sarcosine uptake was then determined using specific competitive inhibitors of 2 amino acid transporter systems, 5-hydroxy-L-tryptophan (HT) for the protoncoupled amino acid transporters (PAT1 gene symbol SLC36A1, PAT2 gene symbol SLC36A2, PAT4 gene symbol SLC36A4) (15) and 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) for system L (16). Thereafter, 11 C-sarcosine was added to cells for 20 min and washed 3 times before counting. Using trypan blue staining, we found cell vitality intact (.95%) after incubation and washing for all samples.
C-Sarcosine Biodistribution
The biodistribution and organ kinetics of 11 C-sarcosine were measured in normal rats and used to estimate human radiation-absorbed doses according to previously described methods (17) . Briefly, the organ distribution of 11 C-sarcosine was determined in 2 male and 2 female Sprague-Dawley rats at 5 time points (5, 15, 30, 60 , and 90 min) using injected doses of 7.4-28 MBq of 11 C-sarcosine. Groups of animals were sacrificed while under isoflurane anesthesia. Organs were quickly removed, weighed, and sectioned for g-counting. The kinetics of elimination of 11 C-sarcosine through urinary excretion were measured with dynamic PET imaging of the bladder in 4 rats (microPET P4 scanner; Siemens). A 1-phase exponential association model was fitted to urinary bladder time-activity data to determine the fraction of the injected dose excreted into urine. The OLINDA/EXM 1.0 software package was used to generate human radiation absorbed dose estimates from the rat biodistribution kinetic data and the urinary excretion data, applying a 4.0-h bladder-voiding interval (18) .
Radiolabeled Sarcosine Metabolites
High-performance liquid chromatography was performed to assess for radiolabeled 11 C-sarcosine metabolites in blood and tissue homogenates of rat prostate and pancreas. On the basis of the known tissue metabolism of sarcosine as a methyl donor, a certain fraction of 11 C-sarcosine is expected to be metabolized to 11 C-CO 2 and exhaled (19) . We measured the cumulative exhaled radioactivity for 11 C-sarcosine (n 5 2), in comparison to 11 C-acetate (n 5 1) and 11 C-choline (n 5 1) as negative control. The radioactivity in breathing air was captured with a commercial activated charcoal filter (EnviroPure) using a closed system and placed into the microPET scanner for 60 min to measure cumulative time-activity curves of exhaled air. We also analyzed volatile radioactivity in tissues, assuming them to be 11 C-CO 2 . Blood, pancreas, and prostate were collected and split into 2 preweighted vials. One was sealed immediately, whereas the other was treated with 8 N) and homogenized. Nitrogen gas was then passed through the mixture for 2 min at about a 10 mL/min flow rate to evaporate the volatile metabolite. The percentage of volatile metabolite from each sample was calculated on the basis of activity loss and tissue weight.
Target Metabolite Analyses
Absolute quantification of choline, glycine, and sarcosine in tumor tissue was determined by target metabolite validation using assays based on gas chromatography-mass spectrometry in human prostate cancer tissues and compared with normal prostate tissues collected by the institutional prostate tissue core. Briefly, frozen tissues were homogenized in methanol after being spiked with labeled internal standards (d 3 -sarcosine and 13 C-glycine) and extracted using a 1:1 volume ratio of water to chloroform. The aqueous methanolic layer was collected and dried, and the extract was azeotroped twice with dimethylformamide. Dimethylformamide (100 mL) and N-methyl-N-tert-butylmethylsilyltrifluoroacetamide 1 1% t-butyl-dimethylchlorosilane were added and incubated at 60°C for 1 h. Selective ion monitoring was used for quantification. The amount of sarcosine and glycine was quantified by measuring the peak area of the native sarcosine (m/z 5 232) to that corresponding to spiked isotope-labeled sarcosine (m/z 5 235) and the native glycine (m/z 5 218) to that of spiked labeled glycine (m/z 5 219), respectively. The levels of sarcosine and glycine were normalized to the tissue weight (in nmol/mg).
Choline was extracted from tissues by liquid-liquid extraction (MeOH:H 2 O:CHCl 3 , 1:1:1 ratio). Tissues were homogenized after the internal standard ( 13 C, d 4 -choline chloride) was spiked. The aqueous methanolic layer containing choline was evaporated to dryness. After being cooled, 50 mL of pyridine and 100 mL of N,O-Bis(trimethylsilyl)trifluoroacetamide were added and heated at 70°C for 60 min. The reaction mixture was dissolved in ethyl-acetate and injected for gas chromatography-mass spectrometry. The amount of choline was calculated by measuring the peak area of the native choline (m/z 5 146) to that corresponding to spiked isotope-labeled choline (m/z 5 151).
11 C-Sarcosine and 11 C-Choline Small-Animal PET Nude mice bearing DU-145 (n 5 10) and PC-3 (n 5 7) tumors received 11 C-sarcosine (27.2 6 13 kBq) intravenously through a bolus tail injection, and 30-min dynamic small-animal PET was performed. After near-complete decay to less than 2% of the initial dose, a dynamic 11 C-choline (28 6 9 kBq) scan was obtained in the same position to ascertain identical tumor position between scans and to avoid bias due to rapidly growing tumors.
Data Reconstruction and Analysis
Images were corrected for decay, scatter, and photon attenuation using a 68 Ge rod source. Time-activity curves of volumes of interest were obtained from dynamic image datasets defined for major organs and tumors to calculate tumor-to-muscle background ratios (TBR). The inspection of time-activity data indicated that the TBRs of 11 C-sarcosine and 11 C-choline were relatively stable between 5 and 20 min. We therefore selected this time interval for the comparison of the TBRs of both tracers.
First Human Subject
After internal review board approval and obtaining written consent, a patient with Gleason 4 1 3 primary prostate cancer received 606 MBq of 11 C-sarcosine for PET/CT scanning (Biograph 40 TrueV mCT; Siemens). Anatomic 3-T MRI was performed separately (Ingenia; Philips). PET data were registered with the 3-dimensional T2-weighted MRI using commercial software (MIM Maestro Software) (20, 21) . The 3-dimensional T2-weighted sequence was then used for targeted transrectal prostate biopsies with a commercial system (UroNav; Invivo).
Statistics
Statistical analyses were performed using JMP 12 (SAS). For paired data ( 11 C-sarcosine vs. 11 C-choline), a paired Wilcoxon test was performed. For tissue metabolites, ANOVA followed by StudentNewman-Keuls tests were performed. Data are presented as mean 6 SD, when appropriate, and P values less than 0.05 were considered statistically significant. 
RESULTS
Small-Animal PET
Both 11 C-sarcosine and 11 C-choline showed intense radiotracer uptake in the intestine and kidneys (Table 1) . Similar to 11 C-choline, the urinary excretion of radioactivity from 11 C-sarcosine was limited. 11 C-sarcosine liver uptake was elevated compared with the mediastinum, but was markedly lower than the hepatic 11 C-choline uptake. Low 11 C-choline uptake was noted in the brain, but 11 C-sarcosine uptake in the brain was nearly absent (Fig. 3) .
Time-activity curves of 11 C-sarcosine showed rapid tumor uptake in both tumor models, with relatively stable TBR at 5 min after injection. All 17 DU-145 and PC-3 tumors were visually identified on 11 C-sarcosine PET, but only 12 of 17 (71%) were noted with 11 C-choline. The TBR (at 5-20 min) for 11 C-sarcosine was significantly elevated compared with 11 C-choline in both tumors models (Fig. 3) . The 11 C-sarcosine TBR of DU-145 tumors was 1.92 6 0.11 compared with 1.41 6 0.13 for 11 C-choline (P , 0.002). Similarly, the TBR of PC-3 tumors was 1.89 6 0.2 for 11 C-sarcosine and 1.34 6 0.16 for 11 C-choline (P , 0.002).
Cell Assays
The 11 C-sarcosine uptake of PC-3 and LNCaP cells could be blocked with an excess of nonradiolabeled (cold) sarcosine (LNCaP: decrease to 3.2% 6 0.7% at 1.125 mMol/mL; PC-3: decrease to 1.1% 6 0.4% at 7.5 mMol/mL), confirming a specific . Both tracers display intense renal uptake (red arrows). Brain uptake (yellow arrows) is essentially absent for 11 C-sarcosine, whereas 11 C-choline brain uptake is low. Cumulative exhaled mean (±SD) radioactivity (as % injected dose) representing 11 C-CO 2 (E) was measured in healthy rats after intravenous injection of 11 C-sarcosine (•), 11 C-acetate (○), and 11 C-choline (▼). transport mechanism of sarcosine into cells. The PAT inhibitor HT and the system L inhibitor BCH were tested at 0.015 mMol/mL concentrations. After HT incubation, 11 C-sarcosine uptake of PC-3 cells decreased to 22.7% 6 7.6% in a dose-dependent fashion. 11 C-sarcosine uptake of LNCaP cells could be almost completely blocked by HT to 9.6% 6 4.3% compared with controls, confirming PAT-dependent transport of 11 C-sarcosine. Because sarcosine is not an L-amino acid, BCH had little effect on 11 C-sarcosine uptake of both cell lines (reduction to 87.9% 6 33.6% for PC-3 and to 85.0% 6 13.0% for LNCaP).
Radiation Dosimetry Estimates
The biodistribution of 11 C-sarcosine obtained from rats was used to calculate human radiation absorbed dose estimates ( Table 1 ). The maximum percentage injected dose observed in the gastrointestinal tract (9.0%) was assumed to enter the small intestine. Also, on the basis of separate rat small-animal PET studies, 2.6% 6 1.4% of the injected dose were excreted via the urinary bladder with a biologic half-time of 0.152 6 0.081 h. Absorbed dose estimates are shown for the reference adult male organ model in Table  2 . The organs with the highest absorbed dose estimates were the small intestine followed by the kidneys. The effective dose was 0.0045 mSv/MBq, resulting in 2.68 mSv for human subjects (at 600 MBq administered dose).
Radiolabeled Metabolite Analyses
No aqueous radiolabeled metabolites of 11 C-sarcosine in blood, prostate, or pancreas were detected at any time point. We concluded that the radiolabeled methylgroup of 11 C-sarcosine is eliminated from the aqueous pool because of SARDHmediated conversion to glycine (Fig. 1) . This was further substantiated by capturing radioactivity in the exhaled air, indicating production of 11 C-CO 2 . Cumulative timeactivity curves obtained from expiratory air indicated that approximately 7% of the injected dose was exhaled as 11 C-CO 2 over a period of 60 min, which was markedly less compared with 11 C-acetate, another known methyl-donor. In the case of 11 C-acetate, the filter was unable to capture all exhaled 11 C-CO 2 from 11 Cacetate (Fig. 3E) . The cumulative time-activity curve obtained after 11 C-sarcosine administration was flat from about 30 to 60 min, indicating that practically all 11 C-CO 2 was exhaled within 30 min. The amount of radioactivity detected in the expired air after 11 C-choline administration (as negative control) was negligible.
We further determined the volatile 11 C-CO 2 fraction of radioactivity within blood, pancreas, and prostate in 1 animal per time point (15, 30 , and 60 min after administration). The 11 C-CO 2 fraction ranged from 14% to 21% in blood, 9% to 23% in prostate, and 12% to 24% in pancreas. Thus, a substantial majority of radioactivity was related to 11 C-sarcosine and not 11 C-CO 2 in every measured tissue at all time points.
Human Subject Figure 4 shows hybrid PET/CT images of the first human subject injected with 11 C-sarcosine. Early-time-point images (between 5 and 10 min after injection) displayed focally increased uptake in the right anterior transition zone of the prostate gland and no significant uptake within contralateral benign prostatic hyperplasia nodules. Registration of PET with T2-weighted MR images revealed a low-signal intensity lesion at this location, measuring 1.04 mL on T2-weighted MR. A Gleason 4 1 3 prostate cancer was identified using image-guided prostate biopsy, whereas standard biopsies were negative. Time-activity curves demonstrated preferential 11 C-sarcosine uptake in the tumor compared with the total prostate and the arterial blood with stable lesion-to-background ratio over time (Fig. 5) .
Metabolite Analyses
Human prostate tissue concentrations of choline (n 5 6) increased significantly from benign (0.17 6 0.05) to localized (0.28 6 0.08) and metastatic (0.42 6 0.08 nmol/mg) prostate cancer (statistical significance levels as listed in Fig. 6 ). Similarly, glycine (n 5 10) showed significant stepwise increases from benign prostate tissues (1.21 6 0.18) to localized (1.67 6 0.41) to metastatic (4.07 6 1.53 nmol/mg) prostate cancer, with sarcosine (n 5 10) displaying the largest gains (benign: 1.54 6 0.6; localized: 3.82 6 2.08; metastatic prostate cancer: 15.57 6 8.0 pmol/mg).
DISCUSSION
We identified increased 11 C-sarcosine uptake (relative to background) in 2 preclinical human prostate cancer xenograft models, with moderate improvement over 11 C-choline. Furthermore, initial human data are promising in a case of low-volume organ-confined prostate cancer, further substantiating a utility for human use. We considered 11 C-sarcosine for prostate cancer imaging because metabolomic data indicated strongly elevated tissue levels in localized prostate cancer, particularly in metastatic disease (3) . Also, the mere addition of sarcosine to cultured benign prostate epithelial cells induced an invasive phenotype (4) . Although the sarcosine metabolism is well-characterized, its metabolic functions in the human body are still poorly understood and are currently under active investigation (5, 22) .
Radiolabeled 11 C-sarcosine is chemically identical to the nonproteinogenic amino acid sarcosine. The known metabolism of (unlabeled) sarcosine consists of 2 biochemical pathways occurring in mitochondria. The first pathway is the oxidative pathway of choline via betaine and dimethylglycine (Fig. 1) . Here, the enzyme SARDH plays a critical role in the conversion to glycine. The second pathway involves methionine with donation of a methyl-group via S-adenosylmethionine to glycine. Here, glycine N-methyltransferase acts as an essential component that influences synthesis of sarcosine from glycine (23) . Because 11 C-sarcosine is not a substrate in either pathway, we consider 11 C-sarcosine cell uptake not to reflect the activity of these sarcosine production pathways.
Sarcosine is a known ligand of the PAT family, which are thought to be multipurpose carriers with distinct roles in different cells (24) . PAT1/PAT2 are low-affinity carriers that mediate 1:1 symport of protons and small amino acids such as glycine, alanine, proline (25) , and g-aminobutyric acid into neurons. PAT4 is a high-affinity, low-capacity electroneutral transporter of neutral amino acids (26) . Baseline PAT expression is ubiquitous (15) and resides at the cell surface and intracellular membranes (endosomes, lysosomes) (27) . Elevated PAT expressions have been linked to cell proliferation (24) . Here, PATs function as part of an amino acid-sensing engine that drives activation of the mammalian target of rapamycin complex 1 (mTORC1) (27) . Physiologically high PAT1/PAT2 expressions have been identified in the brain, pancreas, kidney, duodenum, and small intestine (24) . SLC36A2 expression has been documented at the apical surface of the human proximal renal tubule, where PAT2 functions in the reabsorption of amino acids (24) . Within the intestinal tract, PAT1 plays an important role as nutrient and drug transporter (28) . PAT4 (SLC36A4) is abundantly expressed in excitatory and inhibitory neurons as well as epithelial cells (26) . In cancer, PAT4 is particularly important for the amino acid-dependent activation of the mTORC1 pathway, which is upregulated in prostate and colon cancer, where PAT4 overexpression has been linked to an aggressive phenotype (29) .
In prostate cancer cells, 11 C-sarcosine uptake could be blocked with cold sarcosine, which confirmed a specific transport mechanism for sarcosine and suggests transport as the rate-limiting step. The dose-dependent inhibition of 11 C-sarcosine uptake by the PAT inhibitor HT and the lack of significant inhibition by BCH are consistent with the literature surrounding sarcosine. Although we have not verified PAT expression in the tested PC-3 and LNCaP cancer cell lines, we nevertheless concluded that transport of 11 C-sarcosine into cells is PAT-mediated.
The 11 C-sarcosine biodistribution in normal rats indicated elevated uptake in the pancreas and kidneys; moderate uptake in the liver, stomach, lungs, and adrenals; and low uptake in all other major parenchymal organs. The elevated 11 C-sarcosine uptake in the pancreas and kidneys is likely related to PAT1/PAT2-regulated transport. However, 11 C-sarcosine uptake in rat brain was found to be low despite neuronal PAT1 expression. Also, organs with elevated SARDH protein expression (high protein levels are found in the liver, pancreas and adrenal glands (30)) might also have elevated 11 C-sarcosine uptake, which-based on our biodistribution dataappears to be the case.
Radiation dosimetry estimates for 11 C-sarcosine resulted in an effective dose of 0.0045 mSv/MBq, which is similar to that of 11 C-choline and compares favorably to 18 F-FDG and many other 11 C-labeled radiopharmaceuticals (31) . Our absorbed radiation dose measurements confirmed that 11 C-sarcosine can be safely administered to humans.
11 C-choline and 18 F-fluorocholine are widely used PET radiotracers for prostate cancer imaging (9, 20) , but also 11 C-methionine and 11 C-acetate PET have been successfully tested for this indication (32, 33) . 11 C-choline is known to be rapidly transported into human cancers, including prostate cancer. Although the uptake of 11 C-choline has been linked to the choline kinase activity in prostate cancer (34), a substantial fraction of 11 C-choline may remain nonmetabolized intracellularly (35) , indicating that choline transport and not phosphorylation may be key to 11 C-choline uptake into certain cancer cells. In this context, one potential basis for elevated sarcosine tissue levels would be the upregulation of the oxidative pathway of choline to glycine. In fact, when 11 C-choline was used, it was determined that oxidation of choline is the dominant metabolic pathway in HCT116 tumor xenografts (36) . Our data obtained from human tissues indicate significantly increased choline, sarcosine, and glycine tissue levels in prostate cancer and particularly in metastatic disease compared with benign prostatic tissues. These data are compatible with an upregulation of both metabolic pathways leading to sarcosine production: the methylation from glycine via glycine-N-methyltransferase and the oxidative pathway of choline. Although activation of these pathways will increase the sarcosine tissue concentration, we consider the 11 C-sarcosine uptake only to reflect PAT transport activity and not the magnitude of the sarcosine tissue pool.
Our metabolite analyses did not reveal any radiolabeled aqueous metabolites in blood and tissue. We attribute this finding to the fact that with the demethylation of 11 C-sarcosine to glycine by SARDH, the radiolabeled carbon group is ultimately converted to 11 C-CO 2 . Therefore, the measured tissue radioactivity will be determined largely by the sum of (unchanged) 11 C-sarcosine and 11 C-CO 2 . Because 11 C-CO 2 will gradually be removed from tissues, it is unclear whether the decrease of radioactivity from tissue over time (as identified by biodistribution studies) is related to 11 C-sarcosine or 11 C-CO 2 . However, we do not believe that the decline in the radioactivity noted in many organs is related to a significant loss of 11 C-CO 2 (Table 1) . Such declines are commonly seen for many 11 C-labeled radiopharmaceuticals without 11 C-CO 2 production, including 11 C-choline as unbound radioactivity is escaping back into the vasculature. Because tissues were quickly excised and placed into air-tight vials for biodistribution, a potential for a loss of radioactivity due to 11 C-CO 2 evaporation was minimized. In fact, the lack of such decline from tumor tissue, in contrast to benign prostate tissues as seen in Figure 5 , may not only indicate prostate cancer, but also may have adverse prognostic implications. First, elevated sarcosine tissue levels and enzymes related to the sarcosine metabolism have been linked to tumor aggressiveness not only in prostate cancer (3, 4) , but also in breast and hepatocellular carcinomas in which increased glycine N-methyltransferase protein expression has been associated with decreased survival (37, 38) . Thus, we postulate that 11 C-sarcosine kinetics (displaying a loss of radioactivity from tumor tissue over time), whether due to demethylation of 11 Csarcosine by SARDH resulting in 11 C-CO 2 production or due to an equilibrium of 11 C-sarcosine with (low) intracellular nonlabeled sarcosine levels, might indicate less aggressive tumor features and may have prognostic value.
CONCLUSION
Despite significant progress, the understanding of PATs and their signaling functions is far from complete. The importance of the activity of SLC36 family amino acid (PAT) transporters in cell proliferation and cancer has only recently been fully recognized (22) . Here, our data suggest that PAT-mediated sarcosine transport is key to 11 C-sarcosine uptake in prostate cancer. 11 C-sarcosine PET allows the assessment of PAT transport in the human body with apparent utility in cancer imaging. The improved tumor visualization with 11 C-sarcosine compared with 11 C-choline seen in xenograft tumor models together with increased sarcosine tumor tissue levels compared with benign prostate tissues indicate a potential role for 11 C-sarcosine PET in human prostate cancer. If proven successful with further human use, this radiotracer exemplifies a new concept for PET imaging of cancer based on proton-coupled SLC36 family amino acid transporters currently undergoing active research.
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